Publications by authors named "Hazal Babadagli"
Background: Patients living in rural settings have poorer access to care and more frequent readmissions after treatment for acute coronary syndrome (ACS) than patients in urban settings. It is unclear what types of medication-related issues are encountered by this cohort and whether pharmacist-led care could resolve them.
Objectives: To describe the issues related to cardiac medications encountered by rural patients after treatment for ACS and the impact of a pharmacist-led virtual follow-up pilot program in this population.
Article Synopsis
- - Antiplatelet therapy (APT) is crucial for preventing atherothrombotic events in patients with cardiovascular disease, and effective strategies need to consider both risk of adverse events and bleeding.
- - The updated Canadian guidelines provide recommendations on APT use for various conditions, including primary prevention, dual therapy duration post-PCI, and treatment of patients with acute coronary syndrome (ACS).
- - These guidelines are based on systematic reviews and meta-analyses, ensuring evidence-based approaches for managing APT in different patient scenarios, including those requiring surgery or oral anticoagulation.
Anticoagulation of HeartMate 3 Left Ventricular Assist Device With Apixaban.
Ann Thorac Surg Short Rep
March 2024
We report a case of a 56-year-old man requiring a HeartMate 3 after a myocardial infarction and limited recovery on a temporary ventricular assist device. Because of several gastrointestinal bleeding complications and nonadherence, his antithrombotic therapy was switched from warfarin and aspirin to apixaban 5 mg twice daily. We also determined several peak anti-factor Xa levels for ongoing monitoring.
View Article and Find Full Text PDFImportance: Pragmatic trials test interventions using designs that produce results that may be more applicable to the population in which the intervention will be eventually applied.
Objective: To investigate how pragmatic or explanatory cardiovascular (CV) randomized clinical trials (RCT) are, and if this has changed over time.
Data Source: Six major medical and CV journals, including New England Journal of Medicine, Lancet, JAMA, Circulation, European Heart Journal, and Journal of the American College of Cardiology.
The Role of Direct Oral Anticoagulants in Patients With Coronary Artery Disease.
J Cardiovasc Pharmacol Ther
March 2019
Despite contemporary management, patients with coronary artery disease (CAD) remain at high risk for thrombotic events. Several randomized controlled trials have evaluated the use of direct oral anticoagulants (DOACs) in patients with CAD, including in the setting of acute coronary syndrome (ACS) and stable CAD, and in patients with concomitant atrial fibrillation. Trials of apixaban and dabigatran in patients with ACS demonstrate no benefit with an increased risk of bleeding.
View Article and Find Full Text PDF